Dipeptidyl peptidase-4 (DPP-4) is a enzyme that is expressed in many different tissues and cell types and that exists in two principal forms: a membrane-anchored complex, which is involved in transmembrane signalling independent of its enzymatic activity, and a circulating soluble protein with preserved enzymatic activity. 1 DPP-4 has mainly been investigated as the enzyme responsible for inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
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A Brief Summary of Clinical Evidence
As many trials on DPP-4 inhibitors are currently ongoing, the body of available evidence on these drugs will be increased in a relevant manner in the next 2-3 years. A summary of clinical trials that have already been published as full papers is reported in 
Combination with Metformin
Adequately sized placebo-controlled trials have shown that both sitagliptin 32 and vildagliptin 33 reduce HbA 1c by 0.6-1.1% when used as add-on therapies in patients failing with metformin monotherapy, with an effect that is sustained for up to one year. 17 In one 52-week trial comparing sitagliptin with glipizide, both in combination with metformin, the DPP-4 inhibitor was as effective as the sulphonylurea, but without hypoglycaemic risk and weight gain. 28 
Combination with Thiazolidinediones
In patients inadequately controlled by pioglitazone monotherapy, the addition of vildagliptin 34 or sitagliptin 35 
Combination with Insulin
One 24-week placebo-controlled trial on an adequately sized sample of type 2 diabetic patients on insulin monotherapy showed that the addition of vildagliptin improved metabolic control while reducing the incidence of hypoglycaemia. 36
Safety and Tolerability
DPP-4 inhibitors appear to be extraordinarily well tolerated. Unlike traditional secretagogues (sulphonylureas and glinides), they seem unable to induce hypoglycaemia, even at the highest doses; in fact, in randomised clinical trials, the incidence of hypoglycaemia is not different from that of placebo. In insulin-treated patients, the addition of DPP-4 inhibitor could even reduce the incidence of hypoglycaemic episodes. 36 These results are consistent with the action of GLP-1 and GIP, which are not capable of stimulating insulin synthesis and release when ambient glucose is lower than normal. 1, 37 Treatment 
Extra-glycaemic Effects of Dipeptidyl
Peptidase-4 Inhibitors
Some data suggest that DPP-4 inhibitors could have favourable -although small -effects on lipid metabolism. Sitagliptin has been reported to reduce triglyceride levels in monotherapy 24 and in addition to metformin 32 
